(Q34071600)

30 July 2017

1 reference

title

Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients (English)

1 reference

30 July 2017

Walsh TJ

1

1 reference

30 July 2017

Roden M

series ordinal

2

1 reference

30 July 2017

Roilides E

series ordinal

3

1 reference

30 July 2017

Groll A

series ordinal

4

1 reference

30 July 2017

publication date

1 October 2000

1 reference

International Journal of Antimicrobial Agents

30 July 2017

published in

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

151-156

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Fungal infections complicating acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Nosocomial pneumonia in patients having bone marrow transplant attributable mortality and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Human mycoses: drugs and targets for emerging pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Amphotericin B lipid complex in pediatric patients with invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900242-9

7 January 2021

10.1016/S0924-8579(00)00242-9

Identifiers

DOI

1 reference

30 July 2017

1 reference